Citation Impact
Citing Papers
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
2012
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Cancer immunotherapy beyond immune checkpoint inhibitors
2018
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
Activating a collaborative innate-adaptive immune response to control metastasis
2021
The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy
2018
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
2014
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
2016
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
2020
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Macrophages in immunoregulation and therapeutics
2023 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Cancer-associated cachexia
2018 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Cancer Electrogene Therapy with Interleukin-12
2010
High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy
2020 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
2017
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
MEK Inhibition in the Treatment of Advanced Melanoma
2013
A multi-targeted approach to treating bone metastases
2014
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
2017
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
2020
Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges
2021
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
2009
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Works of Amy Weise being referenced
Prospects of Controlling Breast Cancer Metastasis by Immune Intervention
2007
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
2016
Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression
2009
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors
2015
A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).
2018
Abstract P3-14-05: Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer
2016
Abstract B27: A phase I dose escalation study of the MDM2 inhibitor DS-3032b in patients with advanced solid tumors and lymphomas
2015
A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.
2017
Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors
2011
A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.
2016
A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors.
2017
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.
2016